EUCTR2019-003806-28-HU进行中（未招募）1 期
Phase 1b/2a safety and tolerability study of bemcentinib withpembrolizumab/carboplatin/pemetrexed in subjects with untreatedadvanced or metastatic non-squamous non-small cell lung cancer(NSCLC) without/with a STK11 mutation
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. The subject (or legally acceptable representative, if applicable) must provide written
- •informed consent for the study prior to any screening procedures.
- •2. Be = 18 years of age on the day of signing the informed consent.
- •3. Have a histologically- or cytologically confirmed diagnosis of advanced (Stage IIIb/IIIc)
- •or metastatic (Stage IV) (AJCC Edition 8) non-squamous NSCLC not amenable to
- •curative therapy, irrespective of PD-L1 status and without actionable mutations
- •(Phase 1b).
- •4. Have a histologically- or cytologically confirmed diagnosis of advanced (Stage
- •IIIb/IIIC) or metastatic (Stage IV) (AJCC, Edition 8) non-squamous NSCLC with STK11
- •mutation, not amenable to curative therapy, irrespective of PD-L1 status and without
- •actionable mutations (Phase 2a).
- •5. Participants who received prior neo-adjuvant or adjuvant/consolidation treatment
- •(radiotherapy, chemotherapy, immunotherapy) or chemoradiotherapy with curative
- •intent for non-metastatic disease must have experienced a treatment-free interval of
- •at least 6 months since the last dose of chemotherapy, immunotherapy and/or
- •radiotherapy before enrollment
- •6. Have measurable disease per RECIST 1.1 as assessed by the investigator. Lesions
- •situated in a previously irradiated area are considered measurable if progression has
- •been demonstrated in such lesions.
- •The exhaustive list of the inclusion criteria is available in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •1. Has received any prior chemotherapy or biological therapy for advanced
- •(Stage IIIb/IIIc) or metastatic (Stage IV) non-squamous NSCLC.
- •2. Has any actionable mutation that is considered targetable with first-line treatment.
- •3. Has a known history of prior malignancy except if the subject has undergone
- •potentially curative therapy with no evidence of disease recurrence for 3 years since
- •initiation of that therapy.
- •4. Has known active central nervous system (CNS) metastases and/or carcinomatous
- •meningitis. Subjects with previously treated brain metastases may participate,
- •provided they are radiologically stable, i.e. without evidence of progression for at least
- •2 weeks and have no evidence of new or enlarging brain metastases and are off steroids
- •7 days prior to dosing with study medication. Stable brain metastases by this definition
- •should be established prior to the first dose of study medication. Subjects with
- •asymptomatic brain metastases (i.e. no neurological symptoms, no requirements for
- •corticosteroids, and no lesion >1.5cm) may participate but will require regular imaging
- •of the brain as a site of disease.
- •5. History of the following cardiac conditions:
- •a. Congestive cardiac failure of >Grade II severity according to the NYHA or
- •resistant or inadequately treated heart failure.
- •b. Ischemic cardiac event including myocardial infarction or hospitalization for
- •unstable angina within 3 months prior to first dose.
- •c. Abnormal left ventricular ejection fraction on echocardiography or multigated
- •acquisition scan (MUGA) (less than the lower limit of normal for a subject of
- •that age at the treating institution or <45%, whichever is lower).
- •d. Uncontrolled cardiac disease, including unstable angina, uncontrolled
- •hypertension (i.e. sustained systolic blood pressure (BP) >160 mmHg or
- •diastolic BP >90 mmHg), or need to change medication due to lack of disease
- •control within 12 weeks prior to the provision of consent.
- •e. History or presence of sustained bradycardia (=55 bpm) or history of
- •symptomatic bradycardia, left bundle branch block, cardiac pacemaker or
- •significant arrhythmias as defined by the need for treatment.
- •f. Family history of long QTc syndrome or ventricular arrhythmias; personal
- •history of long QTc syndrome or previous drug induced QTc prolongation of at
- •least Grade 3 (QTc >500ms).
- •g. Presence of any other risk factors that increase the risk of QTc prolongation,
- •specifically, hypokalemia or hypomagnesemia (if corrected the subject may be
- •enrolled) or inadequately treated hypothyroidism (defined as thyroid
- •stimulating hormone (TSH) below the expected range).
- •h. Current treatment with any agent known to cause QT prolongation and have a
- •risk for Torsades de pointes (TdP), which cannot be discontinued at least 5 and
- •½ half-lives or 2 weeks prior to the first dose of study treatment, with the
- •exception of antiemetics (e.g. ondansetron) which may be required. Please see
- •https://crediblemeds.org for a list of medications with known Torsade de Point
- •risk that need to be excluded.
- •The exhaustive list of the exclusion criteria is available in the protocol.
研究者
相似试验
进行中（未招募）
1 期
A safety and efficacy study of the drug BGB-290 in combination with radiation therapy and/or temozolomide (TMZ) in patients with brain cancer.glioblastomaEUCTR2017-001554-33-NLBeiGene USA, Inc.300
已完成
不适用
Phase 1b study of safety and tolerability in patients treated with stereotactic radiotherapy combined with durvalumab and tremelimumab in stage 4 NSCLCNon-small cell lung cancer (NSCLC)10038666NL-OMON44296niversitair Medisch Centrum Groningen25
已完成
不适用
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination with AMG 404 in Subjects with Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)malignent brain tumorspongioblastoom10029211NL-OMON48548Amgen26
进行中（未招募）
1 期
A Study of Tarlatamab in Participants With Neuroendocrine Prostate Cancer (DeLLpro-300)JPRN-jRCT2031210415Tagashira Shuzo60
撤回
不适用
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaKahler's diseaseplasma cell myelomaRelapsed or Refractory Multiple Myeloma10018865NL-OMON46679Amgen3